Skip to content

Elicio Therapeutics, Inc.

ELTX

CIK 0001601485 · Pharmaceutical Preparations · Nasdaq

  • Angion Biomedica Corp. (until 2023-05-30)
← back to feed
Revenue (TTM)
$2.3M
−91.9% YoY Q1 May 2026
Net Income (TTM)
−$43.68M
+23.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.78
+39.3% YoY Q1 May 2026
Gross Margin
84.9%
Q1 May 2026
Operating Margin
-1,715.5%
Q1 May 2026
Net Margin
-1,898.1%
Q1 May 2026
Free Cash Flow (TTM)
−$42.08M
Q1 May 2026
Cash
$14.95M
Q1 May 2026
Total Debt
$9.48M
Q1 May 2026
Shares Outstanding
19.09M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings